GlassScriptPhysician profile
Roberta Anderson-Oeser
NPI 1083670558
$3,544.66
in general payments reported to CMS, 2019-2025
27 companies · $597 in 2025
The $597 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $18.32 · 2021: $615 · 2022: $828 · 2023: $918 · 2024: $467 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.24 | 2021-2025 | Botox, Ubrelvy |
| Medtronic, INC. | $479.85 | 2021-2024 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.96 | 2021-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $179.86 | 2019-2022 | |
| Tersera Therapeutics LLC | $142.01 | 2021-2025 | Prialt |
| Lundbeck LLC | $106.74 | 2022-2025 | Vyepti |
| Fidia Pharma USA INC. | $96.45 | 2022-2025 | Hymovis, Triluron, Hyalgan |
| Abbott Laboratories | $89.46 | 2021-2023 | Proclaim |
| Averitas Pharma INC. | $85.63 | 2023 | Qutenza |
| Pfizer INC. | $72.91 | 2025 | |
| Grt US Holding, INC. | $62.12 | 2022 | |
| Nevro Corp. | $57.83 | 2021-2024 | Senza |
| Boston Scientific Corporation | $50.77 | 2021-2024 | |
| Amgen INC. | $49.46 | 2021 | |
| Allergan, INC. | $48.11 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $46.23 | 2019-2020 | |
| Redhill Biopharma INC. | $45.61 | 2021 | |
| Collegium Pharmaceutical, INC. | $41.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.52 | 2021 | |
| Bioventus LLC | $25.89 | 2022-2023 | Durolane |
| Ultragenyx Pharmaceutical INC. | $23.39 | 2021 | |
| Pacira Therapeutics, INC. | $19.16 | 2021 | |
| Si-Bone, INC. | $19.13 | 2025 | |
| Shionogi INC | $18.96 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.33 | 2025 | Horizant |
| Biodelivery Sciences International, INC. | $15.18 | 2019 | |
| Lilly USA, LLC | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Anderson-Oeser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.